BioCentury | Jun 21, 2010
Finance

Regulatory milestones

...expected historical CR of about 14%. The antisense compound binds to the R2 component of ribonucleotide reductase mRNA...
BioCentury | Jun 21, 2010
Clinical News

LOR-2040: Phase II data

...GTI-2040) Business: Cancer Molecular target: Ribonucleotide reductase mRNA Description: Antisense compound that binds to R2 component of ribonucleotide reductase mRNA...
BioCentury | Jun 15, 2010
Clinical News

Lorus reports LOR-2040 data

...enrolled 25 patients. LOR-2040 is an antisense compound that binds to the R2 component of ribonucleotide reductase mRNA...
BioCentury | Sep 7, 2009
Regulation

On deck in AML

...Lorus Therapeutics Inc. (TSX:LOR) LOR-2040 (GTI 2040) Antisense compound that binds to R2 component of ribonucleotide reductase mRNA...
BioCentury | Jul 7, 2008
Clinical News

LOR-2040: Phase I data

...Business: Cancer Molecular target: Ribonucleotide reductase mRNA Description: Antisense compound that binds to R2 component of ribonucleotide reductase mRNA...
BioCentury | Jun 30, 2008
Clinical News

LOR-2040 regulatory update

...treat acute myeloid leukemia (AML). The antisense compound that binds to the R2 component of ribonucleotide reductase mRNA...
BioCentury | Apr 28, 2008
Clinical News

LOR-2040: Bridging study start

...Business: Cancer Molecular target: Ribonucleotide reductase mRNA Description: Antisense compound that binds to R2 component of ribonucleotide reductase mRNA...
BioCentury | Sep 3, 2007
Clinical News

GTI-2040: Phase II started

...GTI-2040 Business: Cancer Molecular target: Ribonucleotide reductase mRNA Description: Antisense compound that binds to R2 component of ribonucleotide reductase mRNA...
BioCentury | Jun 25, 2007
Clinical News

GTI-2040: Phase I started

...GTI-2040 Business: Cancer Molecular target: Ribonucleotide reductase mRNA Description: Antisense compound that binds to R2 component of ribonucleotide reductase mRNA...
BioCentury | Jun 26, 2006
Clinical News

GTI-2040: Phase I start

...GTI-2040 Business: Cancer Molecular target: Ribonucleotide reductase mRNA Description: Antisense compound that binds to R2 component of ribonucleotide reductase mRNA...
Items per page:
1 - 10 of 27